UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
MyoKardia, Inc.
(Name of Subject Company)
MyoKardia, Inc.
(Name of Persons Filing Statement)
COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE
(Title of Class of Securities)
62857M105
(CUSIP Number of Class of Securities)
Denelle Waynick
MyoKardia, Inc.
General Counsel & Corporate Secretary
1000 Sierra Point Parkway
Suite 1300
Brisbane, CA 94005
(650) 741-0900
With copies to:
Stuart M. Cable, Esq.
Lisa R. Haddad, Esq.
Michael R. Patrone, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Myokardia, Inc. on October 5, 2020 (including all exhibits attached thereto) is incorporated herein by reference.